If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Evinova will operate as a separate health-tech business within AstraZeneca
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
